肺腺癌中 EML4-ALK 外显子 19 融合变体的鉴定及艾乐替尼耐药。
Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.
机构信息
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Shanghai Key Laboratory of Radiation Oncology, Shanghai, People's Republic of China.
School of Biological Sciences, University of Nebraska, Lincoln, NE, USA.
出版信息
Lung Cancer. 2021 Oct;160:32-35. doi: 10.1016/j.lungcan.2021.07.020. Epub 2021 Aug 6.
Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown a high response rate and long progression-free survival in primary treatment of ALK-positive non-small-cell lung cancer (NSCLC). De novo resistance or refractory subtype is rare event. Herein, we identify the first case with serial next-generation sequencing (NGS) results that harboured a rare echinoderm microtubule associated protein like 4 gene (EML4) -ALK (breaking site at exon 19) fusion in a lung adenocarcinoma (LUAD) patient who acquired alectinib resistance rapidly (less than 3 months), followed by multi-drug resistance and short survival time.
艾乐替尼是一种高度选择性的间变性淋巴瘤激酶（ALK）抑制剂，在 ALK 阳性非小细胞肺癌（NSCLC）的一线治疗中显示出高应答率和长无进展生存期。新发耐药或难治亚型是罕见事件。在此，我们通过连续的下一代测序（NGS）结果首次鉴定了一例肺腺癌（LUAD）患者，该患者在不到 3 个月的时间内迅速获得了艾乐替尼耐药（不到 3 个月），随后出现多药耐药和短生存时间，该患者存在罕见的棘皮动物微管相关蛋白样 4 基因（EML4）-ALK（外显子 19 断裂点）融合。
Zotero 插件